Drug Trial Radar · NCT02081378
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Apr 24, 2014
Primary completion
Jun 3, 2021
Study completion Mar 14, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in Chronic myeloid leukemia (CML) and Philadelphia chromosome positive Acute lymphoblastic leukemia (Ph+ ALL) patients who are relapsed or refractory to or are intolerant of Tyrosine kinase inhibitors (TKIs), and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.
Conditions
- Chronic Myelogenous Leukemia
- Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Interventions
Asciminib (ABL001)Drug
Asciminib was be administered orally in a dose escalation schedule.
NilotinibDrug
Asciminib and Nilotinib was administered orally in CML patients
ImatinibDrug
Asciminib and imatinib was administered orally in CML patients
DasatinibDrug
Asciminib and dasatinib was administered orally in CML patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) during the first cycle of study treatmentTime frame: First Cycle is 28 days
Locations
18 sites in 10 countries. Site status is shown where the registry gives one.
Dana Farber Cancer Institute Hematology / Oncology
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center SC
Ann Arbor, Michigan
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering
New York, New York
Oregon Health Sciences University SC-6
Portland, Oregon
University of Texas/MD Anderson Cancer Center UT MD Anderson
Houston, Texas
Huntsman Cancer Institute SC
Salt Lake City, Utah
Novartis Investigative Site
Adelaide, South Australia, Australia
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Paris, Cedex 10, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Jena, Germany
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Kobe, Hyōgo, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, Seocho Gu, South Korea
Novartis Investigative Site
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.